Lixudebart (ALE.F02)
Organ Fibrosis
Phase 2Active
Key Facts
About Alentis Therapeutics
Alentis Therapeutics is a private, clinical-stage biotechnology company headquartered in Basel, Switzerland, and is a leader in targeting Claudin-1 (CLDN1). Its pipeline includes the ADC ALE.P02 for squamous cancers and the monoclonal antibody lixudebart (ALE.F02) for organ fibrosis, both in clinical development. The company was founded on over 15 years of foundational research and is led by a seasoned team, including CEO Mark Pruzanski, a veteran biotech entrepreneur. Alentis aims to address significant unmet needs in oncology and fibrotic diseases through its novel Claudin-1-targeting platform.
View full company profile